These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

145 related articles for article (PubMed ID: 10346413)

  • 1. Thrombolysis, stroke units and other strategies for reducing acute stroke costs.
    Wein TH; Hickenbottom SL; Alexandrov AV
    Pharmacoeconomics; 1998 Dec; 14(6):603-11. PubMed ID: 10346413
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cost-effectiveness of tissue plasminogen activator for acute ischemic stroke. NINDS rt-PA Stroke Study Group.
    Fagan SC; Morgenstern LB; Petitta A; Ward RE; Tilley BC; Marler JR; Levine SR; Broderick JP; Kwiatkowski TG; Frankel M; Brott TG; Walker MD
    Neurology; 1998 Apr; 50(4):883-90. PubMed ID: 9566367
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cost-effectiveness of thrombolysis with recombinant tissue plasminogen activator for acute ischemic stroke assessed by a model based on UK NHS costs.
    Sandercock P; Berge E; Dennis M; Forbes J; Hand P; Kwan J; Lewis S; Lindley R; Neilson A; Wardlaw J
    Stroke; 2004 Jun; 35(6):1490-7. PubMed ID: 15105519
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Intravenous thrombolysis with recombinant tissue plasminogen activator for acute hemispheric stroke. The European Cooperative Acute Stroke Study (ECASS).
    Hacke W; Kaste M; Fieschi C; Toni D; Lesaffre E; von Kummer R; Boysen G; Bluhmki E; Höxter G; Mahagne MH
    JAMA; 1995 Oct; 274(13):1017-25. PubMed ID: 7563451
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Acute Ischemic Stroke (AIS) patient management in French stroke units and impact estimation of thrombolysis on care pathways and associated costs.
    Schmidt A; Heroum C; Caumette D; Le Lay K; Bénard S
    Cerebrovasc Dis; 2015; 39(2):94-101. PubMed ID: 25660476
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A pharmacoeconomic assessment of recombinant tissue plasminogen activator therapy for acute ischemic stroke in a tertiary hospital in China.
    Yan X; Hu HT; Liu S; Sun YH; Gao X
    Neurol Res; 2015 Apr; 37(4):352-8. PubMed ID: 25297471
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cost effectiveness of thrombolytic therapy with tissue plasminogen activator as compared with streptokinase for acute myocardial infarction.
    Mark DB; Hlatky MA; Califf RM; Naylor CD; Lee KL; Armstrong PW; Barbash G; White H; Simoons ML; Nelson CL
    N Engl J Med; 1995 May; 332(21):1418-24. PubMed ID: 7723799
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Recombinant tissue plasminogen activator (rt-PA) utilisation by rural clinicians in acute ischaemic stroke: an audit of current practice and clinical outcomes.
    Williams JM; Navin TJ; Jude MR; Levi CR
    Aust J Rural Health; 2013 Aug; 21(4):203-7. PubMed ID: 24033520
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cost-effectiveness of intravenous thrombolysis with alteplase within a 3-hour window after acute ischemic stroke.
    Ehlers L; Andersen G; Clausen LB; Bech M; Kjølby M
    Stroke; 2007 Jan; 38(1):85-9. PubMed ID: 17122430
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Early neurological deterioration within 24 hours after intravenous rt-PA therapy for stroke patients: the Stroke Acute Management with Urgent Risk Factor Assessment and Improvement rt-PA Registry.
    Mori M; Naganuma M; Okada Y; Hasegawa Y; Shiokawa Y; Nakagawara J; Furui E; Kimura K; Yamagami H; Kario K; Okuda S; Koga M; Minematsu K; Toyoda K
    Cerebrovasc Dis; 2012; 34(2):140-6. PubMed ID: 22854333
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Rationale, design, and progress of the ENhanced Control of Hypertension ANd Thrombolysis strokE stuDy (ENCHANTED) trial: An international multicenter 2 × 2 quasi-factorial randomized controlled trial of low- vs. standard-dose rt-PA and early intensive vs. guideline-recommended blood pressure lowering in patients with acute ischaemic stroke eligible for thrombolysis treatment.
    Huang Y; Sharma VK; Robinson T; Lindley RI; Chen X; Kim JS; Lavados P; Olavarría V; Arima H; Fuentes S; Nguyen HT; Lee TH; Parsons MW; Levi C; Demchuk AM; Bath PM; Broderick JP; Donnan GA; Martins S; Pontes-Neto OM; Silva F; Pandian J; Ricci S; Stapf C; Woodward M; Wang J; Chalmers J; Anderson CS;
    Int J Stroke; 2015 Jul; 10(5):778-88. PubMed ID: 25832995
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pathophysiology and mechanisms of acute ischemic stroke. The NINDS rt-PA Stroke Study Group.
    Bratina P; Rapp K; Barch C; Kongable G; Donnarumma R; Spilker J; Daley S; Braimah J; Sailor S
    J Neurosci Nurs; 1997 Dec; 29(6):356-60. PubMed ID: 9479656
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Trial design and reporting standards for intra-arterial cerebral thrombolysis for acute ischemic stroke.
    Higashida RT; Furlan AJ; Roberts H; Tomsick T; Connors B; Barr J; Dillon W; Warach S; Broderick J; Tilley B; Sacks D; ;
    Stroke; 2003 Aug; 34(8):e109-37. PubMed ID: 12869717
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Nursing care of acute stroke patients after receiving rt-PA therapy. The NINDS rt-PA Stroke Study Group.
    Braimah J; Kongable G; Rapp K; Daley S; Bratina P; Sailor S; Barch C; Donnarumma R; Spilker J
    J Neurosci Nurs; 1997 Dec; 29(6):373-83. PubMed ID: 9479659
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Intravenous thrombolysis patients with acute ischemic stroke: the analysis of the 100 cases. Part I. Characteristic of the patients and effectiveness of treatment].
    Sobolewski P; Sledzińska M; Szczuchniak W; Hatalska-Zerebiec R; Grzesik M; Sobota A
    Przegl Lek; 2012; 69(6):237-41. PubMed ID: 23094435
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Time of day, outcome, and response to thrombolytic therapy: the National Institute of Neurological Disorders and Stroke Recombinant Tissue Plasminogen Activator Stroke Trial experience.
    Rhoney DH; Coplin WM; Lin Y; Frankel M; Lyden PD; Levine SR
    J Stroke Cerebrovasc Dis; 2010 Jan; 19(1):40-8. PubMed ID: 20123226
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cost-Utility analysis of tissue plasminogen activator therapy for acute ischaemic stroke: a Canadian healthcare perspective.
    Sinclair SE; Frighetto L; Loewen PS; Sunderji R; Teal P; Fagan SC; Marra CA
    Pharmacoeconomics; 2001; 19(9):927-36. PubMed ID: 11700779
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cost-effectiveness analysis of thrombolytic treatment for stroke.
    Mar J; Begiristain JM; Arrazola A
    Cerebrovasc Dis; 2005; 20(3):193-200. PubMed ID: 16088115
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cost-effectiveness of thrombolysis within 4.5 hours of acute ischemic stroke: experience from Australian stroke center.
    Tan Tanny SP; Busija L; Liew D; Teo S; Davis SM; Yan B
    Stroke; 2013 Aug; 44(8):2269-74. PubMed ID: 23780955
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Observed Cost and Variations in Short Term Cost-Effectiveness of Therapy for Ischemic Stroke in Interventional Management of Stroke (IMS) III.
    Simpson KN; Simpson AN; Mauldin PD; Palesch YY; Yeatts SD; Kleindorfer D; Tomsick TA; Foster LD; Demchuk AM; Khatri P; Hill MD; Jauch EC; Jovin TG; Yan B; von Kummer R; Molina CA; Goyal M; Schonewille WJ; Mazighi M; Engelter ST; Anderson C; Spilker J; Carrozzella J; Ryckborst KJ; Janis LS; Broderick JP;
    J Am Heart Assoc; 2017 May; 6(5):. PubMed ID: 28483774
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.